KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 8,077 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the transaction, the insider now directly owns 94,199 shares in the company, valued at $872,282.74. This trade represents a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

KalVista Pharmaceuticals Price Performance

Shares of KALV stock opened at $9.28 on Friday. The firm has a 50-day moving average of $11.04 and a 200-day moving average of $11.99. KalVista Pharmaceuticals, Inc. has a one year low of $7.39 and a one year high of $16.88. The company has a market cap of $400.82 million, a P/E ratio of -2.63 and a beta of 0.92.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.04. As a group, research analysts expect that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD increased its holdings in KalVista Pharmaceuticals by 4.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock worth $263,000 after buying an additional 944 shares during the last quarter. HighVista Strategies LLC increased its stake in shares of KalVista Pharmaceuticals by 4.5% during the 3rd quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock worth $386,000 after purchasing an additional 1,432 shares during the last quarter. ClariVest Asset Management LLC raised its holdings in shares of KalVista Pharmaceuticals by 2.8% in the 2nd quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company’s stock worth $673,000 after purchasing an additional 1,535 shares during the period. Nicholas Investment Partners LP lifted its stake in KalVista Pharmaceuticals by 0.9% in the second quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock valued at $2,172,000 after purchasing an additional 1,714 shares during the last quarter. Finally, nVerses Capital LLC bought a new position in KalVista Pharmaceuticals during the second quarter valued at $25,000.

Analyst Ratings Changes

Several brokerages recently weighed in on KALV. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).